Does Cellebrite DI (CLBT) Offer Value After Recent Share Price Weakness? - Yahoo Finance

Does Cellebrite DI (CLBT) Offer Value After Recent Share Price Weakness? Simply Wall St February 22, 2026 4 min read CLBT +1.29% Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. If you are wondering whether Cellebrite DI's share price really lines up with its underlying worth, this article walks through the key valuation angles that matter for you. The stock last closed at US$13.16, with returns of 10.1% decline over 7 days, 17.1% decline over 30 days, 26.2% decline year to date, 31.2% decline over 1 year, 128.1% over 3 years and 26.3% over 5 years, pointing to shifting expectations over different time frames. Recent coverage has focused on Cellebrite DI's role in digital intelligence solutions for law enforcement and enterprise clients, as well as how demand for its tools fits into wider conversations about data, security and compliance. This context helps frame why the market may be reassessing both the opportunity and the risks tied to the business. Cellebrite DI currently has a valuation score of 3 out of 6, which means it screens as undervalued on half of the checks used. Next, we will look at how different valuation methods stack up for the stock, then finish with a practical way to pull all these valuation signals together. Find out why Cellebrite DI's -31.2% return over the last year is lagging behind its peers. Approach 1: Cellebrite DI Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model takes estimates of a company's future cash flows and discounts them back to today, to arrive at an estimate of what the whole business could be worth right now. For Cellebrite DI, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow stands at about $160.3 million. Analysts provide explicit free cash flow estimates out to 2028, with Simply Wall St extrapolating cash flows further out to 2035. Within those projections, free cash flow in 2028 is set at $259 million, and by 2035 the extrapolated figure reaches $426.7 million, all in $. After discounting this stream of projected cash flows back to today, the DCF model arrives at an estimated intrinsic value of about $16.77 per share. With the recent share price at $13.16, the model implies Cellebrite DI trades at a 21.5% discount to this estimate, which screens as undervalued on this measure. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Cellebrite DI is undervalued by 21.5%. Track this in your watchlist or portfolio, or discover 54 more high quality undervalued stocks. CLBT Discounted Cash Flow as at Feb 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Cellebrite DI. Story Continues View Comments Terms and Privacy Policy Privacy Dashboard